Featured Research

from universities, journals, and other organizations

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

Date:
November 9, 2011
Source:
Cardiovascular Research Foundation
Summary:
The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at higher risk, according to results of the DESERT registry.

The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at higher risk, according to results of the DESERT registry. Results of the trial were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Related Articles


Stent thrombosis, a condition in which blood clots form following the implantation of a stent, frequently presents as an acute event triggering myocardial infarction (MI, heart attack) or death. As single center studies are limited in their evaluation of ST, there is an existing need to understand the factors predicting ST and define those patients are that are at highest risk.

DESERT (Drug Eluting Stent Event Registry of Thrombosis), in which 922 patients from 20 sites from the United States, Canada and Switzerland have been enrolled in this multi-center, observational, case-control study of definite, late or very late ST in patients with drug-eluting stents (DES). DESERT is the largest case-control registry of late and very late definite stent thrombosis.

In the registry, the majority of late ST occurred after one year (~75%) and continued for up to 7.3 years. The clinical presentation of late ST was mainly myocardial infarction (66.9% STEMI; 22% NSTEMI). Nearly 30% of the patients with late stent thrombosis were on dual antiplatelet therapy (DAPT) at the time of the event.

"Patients who had first generation drug-eluting stents continue to be at risk for late stent thrombosis up to seven years," said lead investigator, Ron Waksman, MD. Dr. Waksman is Associate Director, Division of Cardiology at Washington Hospital Center (WHC) and Director of Experimental Angioplasty and Emerging Technologies at the Cardiovascular Research Institute (CRI) at WHC.

"Younger patients, smokers, African Americans, patients with multi-vessel disease, STEMI or saphenous vein grafts (SVG) should be reevaluated for drug-eluting stents or for a strong and longer term regimen of dual antiplatelet therapy," Dr. Waksman said.

The DESERT trial was investigation driven study is funded in part by Medtronic Vascular and by the investigators of the study. Dr. Waksman serves on the advisory board of several of the DES manufacturers tested in the study.


Story Source:

The above story is based on materials provided by Cardiovascular Research Foundation. Note: Materials may be edited for content and length.


Cite This Page:

Cardiovascular Research Foundation. "Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified." ScienceDaily. ScienceDaily, 9 November 2011. <www.sciencedaily.com/releases/2011/11/111109161343.htm>.
Cardiovascular Research Foundation. (2011, November 9). Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2011/11/111109161343.htm
Cardiovascular Research Foundation. "Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified." ScienceDaily. www.sciencedaily.com/releases/2011/11/111109161343.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins